The Group is committed to continuous innovation through research and development (R&D). Through R&D, we are able to develop high quality and cost-competitive pharmaceutical products of various dosage forms for our many therapeutic segments. In addition, the sustainability of our products is enhanced through efficient lifecycle management. Our R&D department is responsible for spearheading product development across all our manufacturing sites. We are committed to the development of over 250 new products of various dosage forms as part of a 10-year development programme. Our clinical trials allow us to safeguard the quality, safety as well as efficacy of our product range. We also expanded our product range to include 10 new registered products in 2018. To date, we have developed close to 70 bioequivalent products.